LEVP: "In reality it won't make much difference commercially...." I agree, BUT: It could make a big difference to shareholders, because approval for treatment of the acute indication is one of the required events necessary for LEVP shareholders to receive an additional $0.50 per share from VPHM.
"The first CVR payment of $0.50 per share would become payable when either (i) Cinryze is approved by the FDA for acute treatment of HAE and the FDA grants orphan exclusivity for Cinryze encompassing the acute treatment of HAE to the exclusion of all other human C1 inhibitor products or, (ii) orphan exclusivity for the acute treatment of HAE has not become effective for any third party's human C1 inhibitor product for two years from the later of the date of closing and the date that orphan exclusivity for Cinryze for the prophylaxis of HAE becomes effective.
News 
Market Data 
Discover 
AI
